A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Trial Profile

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Alcoholic hepatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 20 Oct 2015 According to ClinicalTrials.gov, this study has been terminated because of results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated.
    • 17 Oct 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
    • 30 Jul 2015 According to a Vital Therapies media release, as of July 29, 2015, the eighteenth subject has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top